检索结果-南通市图书馆

Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir(WV116)

Frontiers of Medicine 2023年第6期17卷 1068-1079页

作者： Qiuyu Cao Yi Ding Yu Xu Mian Li Ruizhi Zheng Zhujun Cao Weiqing Wang Yufang Bi Guang Ning Yiping Xu Ren Zhao Department of Endocrine and Metabolic Diseases Shanghai Institute of Endocrine and Metabolic DiseasesRuijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Shanghai National Clinical Research Center for Metabolic Diseases State Key Laboratory of Medical GenomicsKey Laboratory for Endocrine and Metabolic Diseases of the National Health CommissionShanghai National Center for Translational MedicineRuijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Department of Infectious Disease Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Clinical Trials Center Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Department of General Surgery Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China

The coronavirus disease 2019(COVID-19)pandemic has stimulated tremendous efforts to develop therapeutic agents that target severe acute respiratory syndrome coronavirus 2 to control viral *** far,a few small-molecule antiviral drugs,including nirmatrelvir-ritonavir(Paxlovid),remdesivir,and molnupiravir have been marketed for the treatment of ***-ritonavir has been recommended by the World Health Organization as an early treatment for outpatients with mild-to-moderate ***,the existing treatment options have limitations,and effective treatment strategies that are cost-effective and convenient for tackling COVID-19 are still *** date,four domestically developed oral anti-COVID-19 drugs have been granted conditional market approval in *** drugs include azvudine,simnotrelvir-ritonavir(Xiannuoxin),leritrelvir,and mindeudesivir(VV11).Preclinical and clinical studies have explored the efficacy and tolerability of mindeudesivir and supported its early use in mild-to-moderate COVID-19 cases at high risk for *** this review,we discuss the most recent findings regarding the pharmacological mechanism and therapeutic effects focusing on mindeudesivir and other small-molecule antiviral agents for *** findings will expand our understanding and highlight the potential widespread application of China's homegrown anti-COVID-19 drugs.

关键词： COVID-19 antiviral drugs mindeudesivir

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：